Institutional Fund
Catalio Capital Management, LP
New York, NYCIK 19581255 filings on record
Portfolio Value
$478.70M
Q1 2026
Holdings
41
Reported positions
New Buys
10
Opened this quarter
QoQ Change
-15.4%
from $565.79M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Dianthus Therapeutics Inc9.8%
- Bridgebio Pharma Inc6.7%
- Ascendis Pharma A/S6.2%
- Bristol-Myers Squibb Co5.3%
- Syndax Pharmaceuticals Inc5.1%
- Gilead Sciences Inc4.8%
- Other62.1%
Portfolio Holdings
41 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Dianthus Therapeutics Inc | 560.3K | $47.02M | 9.8% | −93.3K | Reduced |
| 2 | Bridgebio Pharma Inc | 432.0K | $32.08M | 6.7% | +432.0K | New |
| 3 | Ascendis Pharma A/S | 129.1K | $29.53M | 6.2% | +9.8K | Added |
| 4 | Bristol-Myers Squibb Co | 420.7K | $25.52M | 5.3% | −227.2K | Reduced |
| 5 | Syndax Pharmaceuticals Inc | 1.04M | $24.38M | 5.1% | −153.1K | Reduced |
| 6 | Gilead Sciences Inc | 163.9K | $22.84M | 4.8% | −125.4K | Reduced |
| 7 | Terns Pharmaceuticals Inc | 409.0K | $21.56M | 4.5% | +272.1K | Added |
| 8 | Definium Therapeutics Inc | 1.04M | $19.62M | 4.1% | +1.04M | New |
| 9 | Soleno Therapeutics Inc | 577.8K | $19.35M | 4.0% | +217.5K | Added |
| 10 | Boston Scientific Corp | 299.3K | $18.78M | 3.9% | −61.1K | Reduced |
31 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio